WCM Investment Management LLC Purchases 34,000 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

WCM Investment Management LLC grew its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 36.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 128,074 shares of the medical equipment provider's stock after acquiring an additional 34,000 shares during the quarter. WCM Investment Management LLC owned about 0.18% of Lantheus worth $13,750,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Signaturefd LLC raised its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 92 shares during the period. Silverberg Bernstein Capital Management LLC boosted its stake in Lantheus by 0.4% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock worth $1,834,000 after buying an additional 100 shares in the last quarter. UMB Bank n.a. increased its stake in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after acquiring an additional 126 shares during the period. GAMMA Investing LLC raised its stake in Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after acquiring an additional 146 shares in the last quarter. Finally, Moody National Bank Trust Division boosted its holdings in shares of Lantheus by 1.1% in the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock worth $1,203,000 after acquiring an additional 162 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Trading Up 1.3 %

LNTH stock traded up $1.07 during mid-day trading on Tuesday, hitting $85.15. The stock had a trading volume of 1,791,305 shares, compared to its average volume of 1,002,962. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The firm has a market capitalization of $5.92 billion, a P/E ratio of 13.99 and a beta of 0.51. The firm has a fifty day simple moving average of $106.89 and a 200 day simple moving average of $96.26.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several recent research reports. Redburn Atlantic began coverage on Lantheus in a report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective for the company. Truist Financial restated a "buy" rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday. StockNews.com raised Lantheus from a "hold" rating to a "buy" rating in a research note on Friday. B. Riley increased their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Finally, JMP Securities reduced their price objective on Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.